688016.SHG MicroPort Endovascular MedTech Ltd
- Market cap
- CNY 11.0B
- P/E
- 18.4x
- P/B
- 2.55x
- ROE
- 14.2%
- Dividend yield
- 1.84%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 688016.SHG undervalued?
Graham number688016.SHG trades 44.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MicroPort Endovascular MedTech Ltd fundamental analysis
No fundamental analysis for MicroPort Endovascular MedTech Ltd yet.
MicroPort Endovascular MedTech Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic st…
Full company profileMicroPort Endovascular MedTech Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MicroPort Endovascular MedTech Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 125M | 165M | 231M | 334M | 470M | 685M | 897M | 1.19B | 1.21B | 1.35B | 1.49B |
| Gross Profit | 95.4M | 127M | 181M | 261M | 369M | 531M | 672M | 901M | 876M | 1.35B | 1.10B |
| Operating Income | 44.9M | 73.9M | 105M | 164M | 250M | 363M | 415M | 574M | 661M | 654M | 717M |
| EBITDA | 50.3M | 77.0M | 112M | 174M | 264M | 379M | 439M | 598M | 689M | 688M | 691M |
| Net Income | 41.1M | 63.4M | 90.6M | 142M | 215M | 316M | 357M | 492M | 502M | 563M | 598M |
| EPS | 0.51 | 0.79 | 1.13 | 1.55 | 2.00 | 2.95 | 3.33 | 4.57 | 4.07 | 4.65 | 4.85 |
| Balance Sheet | |||||||||||
| Total Assets | 189M | 224M | 269M | 1.16B | 1.38B | 1.75B | 2.00B | 4.25B | 4.29B | 4.64B | 5.04B |
| Total Liabilities | 65.2M | 36.2M | 52.7M | 89.7M | 142M | 231M | 252M | 383M | 469M | -3.98B | 804M |
| Shareholders' Equity | 123M | 188M | 216M | 1.07B | 1.23B | 1.49B | 1.72B | 3.84B | 3.79B | 3.98B | 4.22B |
| Cash & Short-term Investments | 27.7M | 31.8M | 49.9M | 889M | 1.05B | 1.24B | 977M | 2.97B | 2.17B | 2.14B | 1.74B |
| Total Debt | 713K | 943K | 1.32M | 3.58M | 18.5M | 45.8M | 41.2M | 35.7M | 28.0M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 30.1M | 69.4M | 107M | 143M | 217M | 300M | 334M | 571M | 374M | 573M | - |
| Capital Expenditure | 31.8M | 28.2M | 24.9M | 21.2M | 26.2M | 89.6M | 294M | 190M | 213M | 303M | 215M |
| Free Cash Flow | -1.67M | 41.1M | 81.9M | 122M | 191M | 211M | 39.8M | 368M | 161M | 270M | 147M |
| Ratios | |||||||||||
| ROE | 33.3% | 33.7% | 41.9% | 13.3% | 17.4% | 21.1% | 20.8% | 12.8% | 13.2% | 14.1% | 14.2% |
| ROA | 21.8% | 28.3% | 33.7% | 12.3% | 15.6% | 18.0% | 17.9% | 11.6% | 11.7% | 12.1% | 11.9% |
| Net Profit Margin | 32.8% | 38.4% | 39.2% | 42.5% | 45.6% | 46.1% | 39.8% | 41.5% | 41.6% | 41.7% | 40.1% |
| Debt to Equity | 0.01x | 0.01x | 0.01x | 0.00x | 0.01x | 0.03x | 0.02x | 0.01x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
MicroPort Endovascular MedTech Ltd dividends
- Dividend yield
- 1.84%
- Forward dividend
- 2.60 CNY
- Payout ratio
- 35.8%
- Ex-dividend date
- Oct 20, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 202M | 1.67 | 35.8% |
| 2024 | CNY 450M | 3.65 | 89.7% |
| 2023 | CNY 166M | 1.54 | 33.6% |
| 2022 | CNY 151M | 1.41 | 42.4% |
| 2021 | CNY 64.8M | 0.60 | 20.5% |
| 2020 | CNY 46.8M | 0.44 | 21.8% |
| 2019 | CNY 22.5M | 0.25 | 15.9% |
| 2018 | CNY 64.0M | 0.80 | 70.6% |
| 2017 | CNY 37.4M | 0.47 | 59.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.49:1 on May 14, 2024.
Who owns MicroPort Endovascular MedTech Ltd
- Insiders 40.88%
- Institutions 6.96%
- Public & others 52.16%
- Shares outstanding 123M
- Free float 69.9M
MicroPort Endovascular MedTech Ltd company profile
- Company name
- MicroPort Endovascular MedTech Ltd
- Ticker
- 688016.SHG
- ISIN
- CNE100003MJ5
- Exchange
- Shanghai Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 822
- Fiscal year end
- December
- Address
- No. 1, Lane 3399, Shanghai, China, 201318
- Phone
- 86 21 3813 9300
- Website
- endovastec.com
About MicroPort Endovascular MedTech Ltd
Shanghai MicroPort Endovascular MedTech Co., Ltd. engages in the research and development, manufacturing, sale, and services of aortic, peripheral vascular, and tumor intervention devices in China and internationally. The company offers Fontus, a branched stent graft system in surgical operation; CRONUS, a stent graft system in surgical operation; Hector, a multi-branch thoracic stent graft system; Cratos and Castor, a branched aortic stent graft system; Talos, a thoracic stent graft system; and Hercules, a thoracic stent graft system with low profile delivery system. It also provides Minos, an abdominal aortic stent graft and delivery System; Aorfix, an endovascular device designed for treating abdominal aortic aneurysms; Altura, a device designed for the endovascular repair of abdominal aortic aneurysms; Aegis, a bifurcated aortic stent graft system; and L-REBOA, an aortic occlusion balloon catheter. In addition, the company offers Reewarm PTX, a drug coated balloon PTA catheter; ReeAmber, a PTA balloon dilatation catheter; Reewarm, a PTA balloon dilatation catheter; Ryflumen, a peripheral high-pressure balloon dilatation catheter; and CROWNUS, a peripheral stent system; HawkMaster, a detachable fibered embolization coils; HawkNest, a fibered embolization coils; Veryan BM3D, which is designed for the treatment of symptomatic de novo lesions in the native superficial femoral artery; Vflower, a venous stent system; SeaDragon, a PTA balloon dilatation catheter; Vewatch, a vena cava filter; Vepack, a snare retrieval kit; VeinPro, an endovenous radiofrequency closure system; Reflow-speX, a support catheter; and DEMANTOID, a peripheral vascular guide wire. Further, it provides Tipspear, a transjugular liver access set. Shanghai MicroPort Endovascular MedTech Co., Ltd. was incorporated in 2012 and is based in Shanghai, the People's Republic of China.
MicroPort Endovascular MedTech Ltd management
8- Mr. Qing Zhu Ph.D.GM & Director · born 1981
- Ms. Chun Fang LiAccounting Supervisor & CFO · born 1980
- Mr. Zhenyu YuanDeputy GM, Core Technical Personnel & Employee Representative Director · born 1977
- Mr. Lantao GuoDeputy GM & Core Technical Personnel · born 1966
- Mr. Ke ChenSenior Director · born 1980
- Ms. Dong Mei YanBoard Secretary
- Ms. Hongjie LuCore Technical Staff · born 1983
- Ms. Liwen WangCore Technical Staff · born 1982